Congenital Myasthenic Syndromes - 13/04/18
, Shin J. Oh, MD bRésumé |
The congenital myasthenic syndromes (CMS) are a group of rare genetic conditions characterized by abnormal neuromuscular transmission. Typically, these conditions have been the result of a dysfunctional protein that is present in the presynaptic terminal, the synaptic cleft, or the postsynaptic terminal. Many of these syndromes present within the first few years of life with fluctuating and fatiguable weakness in a distribution similar to myasthenia gravis, although a limb-girdle distribution and late onset are also seen in certain specific types of CMS. Electrodiagnostic testing with repetitive nerve stimulation may be helpful in some forms of CMS.
Le texte complet de cet article est disponible en PDF.Keywords : Congenital myasthenic syndrome, Neuromuscular junction, Safety factor, Acetylcholine receptor, Acetylcholinesterase
Plan
| Disclosure Statement: P.B. Shieh has served as a consultant for Biogen and Sarepta and a speaker for Biogen and Alexion. He has also received research funding from Sarepta, Ionis, Biogen, PTC, Avexis, Ultragenyx, Pfizer, Catalyst, Roche, BMS, Acceleron, Santhera, Sanofi, Summit, Audentes, Italfarmaco, FibroGen, Reata, and Catabasis. S.J. Oh has no conflict of interest to report. |
Vol 36 - N° 2
P. 367-378 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
